Category - Developments

Developments

Titan Pharma to acquire JT-09 to develop ProNeura-based chronic pruritus treatment

Titan Pharmaceuticals (NASDAQ:TTNP) inked an agreement to acquire JT Pharmaceuticals’ kappa opioid agonist peptide, JT-09, for use in combination with Titan’s ProNeura long-term, continuous drug delivery technology, for...

October 28, 2020

Developments

Prevail Therapeutics gets FDA fast track designation for Gaucher disease

Prevail Therapeutics’ (NASDAQ:PRVL) PR001 received FDA fast track designation for the treatment of neuronopathic Gaucher disease. Gaucher disease is a lysosomal storage disorder caused by mutations in the...

October 27, 2020

Developments

Taysha gets FDA rare pediatric and orphan drug designations for Leigh syndrome

Taysha Gene Therapies (NASDAQ:TSHA) received FDA rare pediatric and orphan drug designations for TSHA-104 for the treatment of SURF1-associated Leigh syndrome. Leigh syndrome is a severe neurological disorder that...

October 27, 2020

Developments

Imagin Medical reports agenda for KOL virtual investor event on Oct. 29

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) reported the agenda for its KOL virtual investor event taking place on Oct. 29 at 12:00 pm ET. Presenters include Jim Hutchens, Imagin’s...

October 26, 2020

Developments

Hepion to present on therapeutic approaches to COVID-19; NASH at Oct. 28; Oct. 29 events

Hepion Pharmaceuticals (NASDAQ:HEPA) will present virtually at the Roth Capital “therapeutic approaches for COVID-19” event taking place on Oct. 28 from 9:00 am to 1:20 pm ET; and at the B. Riley Securities...

October 26, 2020

Developments

Titan Pharma in debt settlement pact with Molteni and Horizon

Titan Pharmaceuticals (NASDAQ:TTNP) inked an agreement to settle all of its debt obligations with Molteni & C. dei F.lli Alitti Società di Esercizio and Horizon Credit. The debt was secured with a lien on all assets...

October 26, 2020

Developments

Kezar KZR-616 gets FDA orphan drug designations for two autoimmune disease

Kezar Life Sciences’ (NASDAQ:KZR) KZR-616 received FDA orphan drug designation for the treatment of polymyositis and dermatomyositis, autoimmune inflammatory myopathies with marked morbidity and mortality. KZR-616 is a...

October 23, 2020

Developments

PhaseBio discontinues Phase 2 COVID-19 trial

PhaseBio Pharmaceuticals (NASDAQ:PHAS) discontinued its Phase 2 trial evaluating PB1046 for the treatment of high-risk, hospitalized COVID-19 patients. PB1046 is a long-acting analog of vasoactive intestinal peptide...

October 23, 2020

Developments

BiondVax universal flu vaccine fails Phase 3 trial

A Phase 3 clinical trial of BiondVax Pharmaceuticals’ (NASDAQ:BVXV) M-001 universal flu vaccine did not demonstrate a statistically significant difference between the vaccinated and placebo groups in reduction of flu...

October 23, 2020

Developments

TG Therapeutics gets FDA fast track designation for ublituximab plus umbralisib

TG Therapeutics (NASDAQ:TGTX) received the FDA fast track designation for the ublituximab plus umbralisib for the treatment of chronic lymphocytic leukemia (CLL). Ublituximab is a glycoengineered anti-CD20 monoclonal...

October 21, 2020

Category - Developments

Titan Pharma to acquire JT-09 to develop ProNeura-based chronic pruritus treatment

Prevail Therapeutics gets FDA fast track designation for Gaucher disease

Taysha gets FDA rare pediatric and orphan drug designations for Leigh syndrome

Imagin Medical reports agenda for KOL virtual investor event on Oct. 29

Hepion to present on therapeutic approaches to COVID-19; NASH at Oct. 28; Oct. 29 events

Titan Pharma in debt settlement pact with Molteni and Horizon

Kezar KZR-616 gets FDA orphan drug designations for two autoimmune disease

PhaseBio discontinues Phase 2 COVID-19 trial

BiondVax universal flu vaccine fails Phase 3 trial

TG Therapeutics gets FDA fast track designation for ublituximab plus umbralisib

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter